Evolocumab
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Atherosclerotic Cardiovascular Disease
Conditions
Atherosclerotic Cardiovascular Disease
Trial Timeline
Oct 3, 2017 → Nov 2, 2020
NCT ID
NCT03096288About Evolocumab
Evolocumab is a approved stage product being developed by Amgen for Atherosclerotic Cardiovascular Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03096288. Target conditions include Atherosclerotic Cardiovascular Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (17)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06140095 | Phase 1 | UNKNOWN |
| NCT04539223 | Approved | UNKNOWN |
| NCT03944577 | Phase 2 | Completed |
| NCT03331666 | Approved | Terminated |
| NCT03403374 | Approved | Completed |
| NCT03096288 | Approved | Completed |
| NCT03080935 | Phase 3 | Terminated |
| NCT02957604 | Pre-clinical | Terminated |
| NCT02624869 | Phase 3 | Completed |
| NCT02867813 | Phase 3 | Completed |
| NCT02585895 | Phase 3 | Completed |
| NCT02304484 | Phase 3 | Completed |
| NCT02275156 | Phase 1 | Completed |
| NCT01652703 | Phase 2 | Completed |
| NCT01624142 | Phase 2/3 | Completed |
| NCT01439880 | Phase 2 | Completed |
| NCT01380730 | Phase 2 | Completed |
Competing Products
20 competing products in Atherosclerotic Cardiovascular Disease